Table 1. Baseline characteristics of patients with intracerebral hemorrhage by eGFR levels on admission.
| eGFR mL/min/1.73 m2 | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Variable | Total N = 4036 | ≧90 N = 1149 (28.5%) | 60–89 N = 1746 (43.3%) | 30–59 N = 837 (20.7%) | 15–29 N = 135 (3.34%) | <15 or dialysis N = 169(4.19%) | p-value | ||||||
| Men, N (%) | 2677 | (66.3) | 749 | (65.2) | 1174 | (67.2) | 573 | (68.5) | 82 | (60.7) | 99 | (58.6) | 0.05* |
| Age, year, median (Q1, Q3) | 61.4 | (51.7, 72.9) | 54.2 | (46.1, 61.4) | 63.3 | (53.2, 74.1) | 71.0 | (58.7, 80.2) | 70.0 | (58.5, 79.6) | 60.5 | (52.6, 69.2) | <0.0001# |
| BMI, kg/m2, median (Q1, Q3) | 24.4 | (21.8, 27.5) | 24.7 | (22.1, 27.6) | 24.4 | (22.0, 24.7) | 24.2 | (21.5, 27.1) | 24.0 | (20.6, 26.6) | 22.8 | (20.1, 25.8) | <0.0001# |
| Smoking | <0.0001* | ||||||||||||
| Current | 1061 | (26.3) | 384 | (33.4) | 450 | (25.8) | 164 | (19.6) | 29 | (21.5) | 34 | (20.1) | |
| Past | 408 | (10.1) | 92 | (8.01) | 185 | (10.6) | 105 | (12.5) | 13 | (9.63) | 13 | (7.69) | |
| Etiology | 0.31 | ||||||||||||
| Hypertensive | 3351 | (83.0) | 936 | (81.5) | 1458 | (83.5) | 697 | (83.3) | 112 | (83.0) | 148 | (87.6) | |
| Non-hypertensive | 685 | (17.0) | 213 | (18.5) | 288 | (16.5) | 140 | (16.7) | 23 | (17.0) | 21 | (12.4) | |
| Comorbidity, N (%) | |||||||||||||
| Hypertension | 3496 | (86.6) | 943 | (82.1) | 1517 | (86.9) | 757 | (90.4) | 120 | (88.9) | 159 | (94.1) | <0.0001 |
| AF | 102 | (2.53) | 18 | (1.57) | 36 | (2.06) | 32 | (3.82) | 13 | (9.63) | 3 | (1.78) | <0.0001* |
| Previous stroke history | 739 | (18.3) | 140 | (12.2) | 333 | (19.1) | 197 | (23.5) | 38 | (28.2) | 31 | (18.3) | <0.0001* |
| Ischemic heart disease | 298 | (7.38) | 47 | (4.09) | 108 | (6.19) | 99 | (11.8) | 18 | (13.3) | 26 | (15.4) | <0.0001* |
| Congestive heart failure | 49 | (1.21) | 7 | (0.61) | 12 | (0.69) | 15 | (1.79) | 9 | (6.67) | 6 | (3.55) | <0.0001* |
| Diabetes mellitus | 1048 | (26.0) | 259 | (22.5) | 384 | (22.0) | 254 | (30.4) | 66 | (48.9) | 85 | (50.3) | <0.0001* |
| Systolic blood pressure, mmHg | 177.0 | (153.0, 203.0) | 170.0 | (148.0, 196.0) | 179.0 | (155.0, 202.0) | 181.0 | (157.0, 211.0) | 184.0 | (153.0, 210.0) | 187.0 | (160.0, 215.0) | <0.0001# |
| Laboratory data, median (Q1, Q3) | |||||||||||||
| Cholesterol, mg/dl | 150.0 | (104.0, 192.0) | 156.0 | (112.0, 197.0) | 148.0 | (100.0, 192.0) | 146.0 | (100.0, 187.0) | 145.0 | (110.0, 205.0) | 150.0 | (108.0, 191.0) | 0.37# |
| Hb, g/dL | 14.2 | (12.7, 15.4) | 14.6 | (13.3, 15.6) | 14.4 | (13.2, 15.5) | 13.7 | (12.3, 15.2) | 11.8 | (10.4, 13.3) | 10.6 | (9.30, 11.6) | <0.0001# |
| NIHSS score on admission, median (Q1, Q3) | 8.00 | (3.00, 17.0) | 8.00 | (3.00, 16.0) | 8.00 | (3.00, 15.0) | 9.00 | (3.00, 21.0) | 12.0 | (4.00, 29.0) | 11.0 | (4.00, 25.0) | <0.0001# |
| Medicine use before admission, N (%) | |||||||||||||
| Antiplatelet drugs | 367 | (9.09) | 63 | (5.48) | 162 | (9.28) | 103 | (12.3) | 20 | (14.8) | 19 | (11.2) | <0.0001* |
| Warfarin | 81 | (2.01) | 11 | (0.96) | 31 | (1.78) | 27 | (3.23) | 9 | (6.67) | 3 | (1.78) | 0.004* |
| Lipid lowering drugs | 204 | (5.05) | 42 | (3.66) | 78 | (4.47) | 52 | (6.21) | 18 | (13.3) | 14 | (8.28) | <0.0001* |
*Chi-square test, and
#Kruskal–Wallis test
eGFR, estimated glomerular filtration rate; Q1, 25th percentile; Q3, 75th percentile; BMI, body mass index; AF, atrial fibrillation; Hb, hemoglobin; NIHSS, National Institutes of Stroke Scale